Home
About Us
On Allergy
Patients Organisations
Researchers’ Corner
Patient Testimonials
Resources
- EAACI Publications
- Position Papers
- EAACI interactive resources
  - Worldwide Map of Pollen Monitoring Stations
  - EAACI Explains COVID-19
    The COVID-19 pandemic that has shaped our new reality is a result of ever-increasing human intrusion into habitats of wild animals and the close interaction with them. The SARS-COV-2 virus jumped the species barrier and sparked the first human COVID-19 infections. Global mass travel fueled one of the most explosive pandemics in modern history. The COVID-19 virus affects humans in various ways, find out more by watching our video.
    
    Authors
    
    1 Eva Untersmayr, MD, PhD, Assoc. Prof.; Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria
    
    2 Milena Sokolowska, MD, PhD; Swiss Institute of Allergy and Asthma Research, University of Zurich, Switzerland
    
    3 Ioana Agache , MD, PhD, Prof.; Transylvania University, Brasov, Romania
    
    4 Montserrat Alvaro Lozano, MD, PhD. 1) Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain. 2) Institut de Recerca Sant Joan de Déu, Barcelona, Spain. 3) Universitat de Barcelona, Barcelona, Spain.
    
    5 Laia Alsina Manrique De Lara, MD, PhD; Clinical Immunology and Primary Immunodeficiencies Unit, Pediatric Allergy and Clinical Immunolgy Department, Hospital Sant Joan de Deu, Barcelona, Spain
    
    6 Elisabeth Angier, MRCGP, MSc; University of Southampton, UK
    
    7 Stefania Arasi, MD, PhD; Pediatric Allergology Unit, Department of Pediatric Medicine, Bambino Gesù Children’s research Hospital (IRCCS), Rome, Italy
    
    8 Sarah Ashley, PhD, Murdoch Childrens Research Institute, Australia
    
    9 Barbara Bohle, Department of Pathophysiology, Division of Immunopathology, University of Vienna, Vienna, Austria
    
    10 Matteo Bonini, Department of Cardiovascular and Thoracic Sciences, Catholic University of Rome, Italy
    
    11 Knut Brockow, MD, Prof., Allergy Unit, Department of Dermatology and Allergy Biederstein, Technical University of Munich, Germany
    
    12 Helen Brough, FRCPCH, PhD; 1) Children’s Allergy Service, Evelina London, Guy’s and St. Thomas’ Hospital, London, UK, 2) Department of Women and Children’s Health, School of Life Course Sciences, King’s College London University, London, UK
    
    13 Thomas Chivato, MD, PhD. Prof.; School of Medicine. University CEU San Pablo, Madrid, Spain.
    
    14 Nicolette W. de Jong, PhD, Assoc. Prof.; ErasmusMC, Internal Medicine, section Allergology & Clinical Immunology, Rotterdam, the Netherlands
    
    15 Stefano Del Giacco, Department of Internal Medicine, University of Cagliari, Caligari, Italy
    
    16 Thomas Eiwegger, MD, Assoc. Prof.; 1) Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada; 2) Research Institute, The Hospital for Sick Children, Translational Medicine, Toronto, Canada; 3)Department of Immunology, The University of Toronto, Toronto, Canada.
    
    17 Andrzej Eljaszewicz, PhD; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland
    
    18 Ibon Eguiluz Gracia, Allergy Unit, Hospital Regional Universitario de Malaga. Insituto de Investigacion Biomedica de Malaga (IBIMA) and ARADyAL.
    
    19 Stefanie Eyerich, PhD, Assoc. Prof., Center for Allergy and Environment (ZAUM), Helmholtz Center and Technical University Munich; Germany
    
    20 Wojciech Feleszko, MD, PhD, Assoc. Prof.; Department of Pediatric Respiratory Diseases and Allergy, The Medical University of Warsaw, Warsaw, Poland.
    
    21 Philippe Gevaert, MD, PhD, Upper Airway Research Laboratory (URL), Department of Otorhinolaryngology, Ghent University Hospital, Belgium
    
    22 Martin Glatz, MD, PhD
    
    23 Cristina Gomez-Casado, PhD; Institute of Applied Molecular Medicine, Hospitals Madrid (HM) Group, San Pablo-CEU University, Madrid, Spain, ARADyAL, RD16/0006/0015, Thematic Network and Cooperative Research Centers, ISCIII, Madrid, Spain
    
    24 Jan Gutermuth
    
    25 Karin Hoffmann-Sommergruber, PhD, Assoc. ; Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria
    
    26 Jozef Janda, Department of Clinical Research‐VPH, Vetsuisse Faculty, University of Bern
    
    27 Rodrigo Jimenez-Siaz, PhD, Assist. ; 1) Dept. Immunology & Oncology, National Center for Biotechnology (CNB-CSIC); 2) McMaster Immunology Research Centre (MIRC), Dept. Pathology & Molecular Medicine, McMaster University
    
    28 Kristina Johansson, PhD
    
    29 Marek Jutel, MD, Prof., 1) Department of Clinical Immunology. Wroclaw Medical University, Wroclaw, Poland; 2) ALL-MED Medical Research Institute, Wroclaw, Poland
    
    30 Sandip Kamath, MSc, PhD; Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia
    
    31 Edward Knol, PhD, Assoc. Prof.; Depts. Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands
    
    32 Eugenia Korotchenko, MSc.; Department of Biosciences, Paris-Lodron University of Salzburg, Salzburg, Austria
    
    33 Inge Kortekaas Krohn , PhD, Assist. ; SKIN Research group, Department of Dermatology, Universitair Ziekenhuis Brussel/ Vrije Universiteit Brussel, Brussels, Belgium
    
    34 Susanne Lau, Charité Medical University Berlin, Dpt. of Pediatric Pneumology and Immunology, Germany
    
    35 Maria Luís Marques, MD; Immunoallergology Department, Centro Hospitalar e Universitário do Porto, Porto, Portugal
    
    36 Henry McSorley, MSci, PhD; 1) Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK; 2) Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK
    
    37 Liam O’Mahony, PhD; Prof.; Departments of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland
    
    38 Oscar Palomares, PhD, Assoc. Prof.; Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.
    
    39 Isabella Quinti, MD Department of Molecular Medicine, Sapienza University of Rome, Rome
    
    40 Carmen Riggioni-Viquez, MD 1) Allergy and Clinical Immunology, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore 2) Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
    
    41 Florentina Sava, PhD, Clinical Scientist in Genomics Birmingham Women’s and Children’s Hospital, Birmingham, UK Central and South Genomic Laboratory Hub
    
    42 Mohamed Shamji, Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College, London, UK MRC Asthma UK
    
    43 Peter Schmid-Grendelmeier, Dept. Of Dermatology, University Hospital of Zürich
    
    44 Carsten Schmidt Weber, Immunology Unit, Department of Medicine III, University of Leipzig, Leipzig, Germany
    
    45 Jürgen Schwarze, MD, PhD, Prof.; Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK
    
    46 Anna Sediva, MD, PhD; Department of Immunology, Motol University Hospital, Charles University, Prague, Czech Republic
    
    47 Isabel Skypala, PhD; Royal Brompton & Harefield NHS Foundation Trust, Imperial College, London, UK
    
    48 Hermelijn Smits, PhD; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands
    
    49 Sylwia Smolińska, PhD; Department of Clinical Immunology, Wroclaw Medical University, Poland
    
    50 Olympia Tsilochristou, MD, PhD; Allergy Department, Guy’s & St Thomas’ Foundation Trust”
    
    51 Maria Jose Torres, MD, Prof.; Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA-ARADyAL, Malaga, Spain
    
    52 Margitta Worm, MD, Division of Allergy and Immunology, Dpt Dermatology, Venerology and Allergy, Charité Universitätsmedizin Berlin
    
    53 Valerie Verhasselt, Tolérance Immunitaire, Université de Nice Sophia‐Antipolis, Nice, France
    
    https://youtu.be/Xi-yKxn9TRM
  - EAACI Explains Dietary Diversity
    [vc_row][vc_column][vc_column_text]
    
    Good food and nutrition are vital from birth onwards. When it is time to start giving solid food to babies, it is important to introduce all foods as soon as possible from the age of 6 months. Fruits, vegetables, wholegrain cereals and healthy fats have an especially important role to play in developing the gut microbiota and the immune system. This short and informative animated video will show how to give a baby the best start in life.
    
    For additional content on dietary diversity and infant feeding, visit our page: patients.eaaci.org
    
    Authors:
    
    1. J. Skypala, PhD RD
    
    N.W. de Jong, PhD, Assoc. Prof.
    
    B. Vlieg-Boerstra, PhD RD
    
    K. Grimshaw, PhD RD
    
    E. Angier, MRCGP, MSc
    
    E. Untersmayr, MD, PhD
    
    S. Barni, MD
    
    L. O’Mahony, PhD; Prof.
    
    S. Lau, MD
    
    M. Czarnecka-Operacz, MD
    
    S. Del Giacco, MD
    
    https://www.youtube.com/watch?v=vZLkt1xkTLM&feature=youtu.be
  - EAACI Explains Vaccination
  - EAACI Explains Food Allergy
Contact

Tuberculin Test

The tuberculin test is used to know if a person has had contact with the tuberculosis bacillus or Koch’s bacillus (Mycobacterium tuberculosis).
It is performed injecting a small amount (0.1 mL) of tuberculin (an extract of tuberculosis bacilli) intradermally, that is, into the skin. A small bubble is formed in the skin and disappears in a few minutes. The test is read 48-72 hours after the injection.
The test has no relation to allergy or asthma. It is sometimes performed in asthmatic patients as part of a differential diagnosis. The symptoms of tuberculosis may resemble those of asthma, and the test is performed to rule out tuberculosis.
The test is considered positive it a reaction of induration appears at the point of the injection. A hard raised area appears which can be palpated and is measured in mm. If no induration appears, the test is considered negative, even if some redness can be seen. The test is usually considered positive if the diameter of the induration is at least 5 mm. Sometimes, a larger diameter (10 or even 15 mm) is required to be considered positive, depending on specific conditions of the patient. A positive test means that the patient has had contact with the tuberculosis bacillus, but it does not discriminate whether this has been a recent or a past contact, or whether the bacillus has been cleared or is still active at the body. The doctor will take into account other data or tests to interpret the test. Once the test is positive, it will usually remain positive lifelong. False positive results (the test is positive but the patient has not really had contact with the tuberculosis bacillus) may appear due to contact with other bacteria similar to that of tuberculosis. False negative results (the test is negative even though the patient has really had contact with the bacillus) may appear due to some other diseases or to medical therapies, specially those that cause immunosuppression in the patient, or if the contact with the bacillus has been very recent
The tuberculin test is also called Mantoux test, or Pirquet test, or PPD test.
The injection of tuberculin causes pain, usually tolerable and transient. No specific preparation is needed if you are scheduled for a tuberculin test.